A survey by pharmaceutical company and CRO executives assesses how well various programs convert RWD into usable data.
We have previously described that real-world data has poor use in clinical trials despite the enthusiasm for these analyzes and their performance in the COVID-19 pandemic. In this blog, we look at how data intermediary software affects real-world data usage. Data by itself is not useful on its own. There needs to be an ecosystem wrapped around the data to retain and protect the data and make it usable. We use the term intermediaries/software to refer to the various analytical tools, vendors and consultants in this ecosystem that convert raw data into usable information.
To identify the attributes of data that are driving real-world data adoption, we surveyed 133 pharma and CRO executives. We asked them to rate the importance of various intermediate data/software attributes that are important in selecting a real-world dataset, including the ability to enable analysis and enable evaluation. as well as their cost, reliability, problem solving, flexibility, responsiveness, and understanding of needs.
We averaged the attributes to calculate the overall importance and satisfaction, as well as the difference scores between importance and satisfaction for each attribute. These difference scores are important because they represent the potential growth of real-world data in current/future use or opportunities for growth in the importance/satisfaction gaps.
The overall average for the importance of the intermediate data/software attributes was 7.9, which was higher than the overall average for the real data (μ = 7.3). Also note that there is a relatively narrow range, which suggests that it is difficult to define an attribute to focus on data/software intermediaries. Next, we consider satisfaction with data/software intermediaries.
You can see that the satisfaction scores were lower than the software importance scores.
The mean difference between importance and satisfaction was 1.5, greater than the mean difference between importance and satisfaction with the data. This, along with the higher importance ratings, suggests that there is greater opportunity for real-world data usage growth by focusing on the intermediate data/software aspects rather than the real data. .
For more information on RWD, see this Round table of pharmaceutical executives from March 2022.
Michael HowleyPA-C, MBA, PhD & Pierre MalamisMBA